{"id":"NCT02861014","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)","officialTitle":"An Open-Label Study To Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Multiple Sclerosis Who Have A Suboptimal Response to an Adequate Course of Disease-Modifying Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-09-09","primaryCompletion":"2019-10-25","completion":"2020-12-15","firstPosted":"2016-08-10","resultsPosted":"2021-02-03","lastUpdate":"2022-01-27"},"enrollment":681,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis, Relapsing-Remitting"],"interventions":[{"type":"BIOLOGICAL","name":"Ocrelizumab","otherNames":["RO4964913"]}],"arms":[{"label":"Ocrelizumab","type":"EXPERIMENTAL"}],"summary":"The purpose of this prospective, multicenter, open-label, efficacy, and safety study is to assess the efficacy and safety of ocrelizumab in participants with Relapsing Remitting Multiple Sclerosis (RRMS) who have had a suboptimal response to an adequate course of a Disease-Modifying Treatment (DMT). The study will consist of a Screening period (up to 4 weeks), an Open-label treatment period (96 weeks; with last dose administered at Week 72), and a Follow-up period of at least 2 years.","primaryOutcome":{"measure":"Percentage of Participants With No Evidence of Disease Activity (NEDA) as Per Protocol Defined Events During a 96-Week Period","timeFrame":"Week 96","effectByArm":[{"arm":"Ocrelizumab","deltaMin":74.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":11},"locations":{"siteCount":163,"countries":["Australia","Belgium","Czechia","Denmark","Estonia","Finland","France","Germany","Ireland","Italy","Netherlands","Norway","Spain","Sweden","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["34748672"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":49,"n":680},"commonTop":["INFUSION RELATED REACTION","NASOPHARYNGITIS","HEADACHE","INFLUENZA","URINARY TRACT INFECTION"]}}